SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Frank Vinluan | 10/12/20 | Boston |
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting | Editors | 10/08/20 | Boston |
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter | Frank Vinluan | 10/06/20 | San Francisco |
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug | Frank Vinluan | 09/30/20 | New York |
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs | Frank Vinluan | 09/28/20 | Boston |
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/21/20 | Boston |
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series | Editors | 09/16/20 | Boston |
Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug | Frank Vinluan | 09/15/20 | San Francisco |
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout | Frank Vinluan | 09/14/20 | San Francisco |
Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test | Frank Vinluan | 09/10/20 | San Francisco |
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |